Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Phase 2 Completed 706 enrolled Novo Nordisk A/S

RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes

Timeline

Start: 2015-09-21
Primary completion: 2016-10-13
Completion: 2016-10-13

Publications

Results Lingvay I, Desouza CV, Lalic KS, Rose L, Hansen T, Zacho J, Pieber TR. A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin. Diabetes Care. 2018 Sep;41(9):1926-1937. doi: 10.2337/dc17-2381. Epub 2018 Jul 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Liraglutide	Peptide	0.3 mg	Subcutaneous
Comparator	Liraglutide	Peptide	0.6 mg	Subcutaneous
Comparator	Liraglutide	Peptide	1.2 mg	Subcutaneous
Comparator	Liraglutide	Peptide	1.8 mg	Subcutaneous
Subject	Semaglutide	Peptide	0.05 mg	Subcutaneous
Subject	Semaglutide	Peptide	0.1 mg	Subcutaneous
Subject	Semaglutide	Peptide	0.2 mg	Subcutaneous
Subject	Semaglutide	Peptide	0.3 mg	Subcutaneous

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Summary

Timeline

Publications

Drugs

Indications